Taiwan biotech can take off by overcoming challenges, says Frank Kung, founder of Vivo Capital


Having started three businesses, two of which successfully went public, founder of Vivo Capital Frank Kung set foot in the biotech sector in the 1970s. Thanks to Kung's decades of experiences in investing in biotech firms in the US and Greater China, Vivo Capital has made itself the largest biotech venture capital fund in Chinese communities worldwide, managing over US$1.7 billion in capital including the Taiwan Silicon Valley Technology Fund.



from Biotech News